Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
about
Update on pathogenesis and treatment of CLEDrugs derived from phage display: from candidate identification to clinical practiceUmbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical studyEffect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus.Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review.A rare case of prototheca algaemia in a patient with systemic lupus erythematosus and recent belimumab infusion.Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis.Belimumab in Systemic Lupus Erythematosus.A case of central nervous system nocardiosis in a patient with lupus treated with belimumab.Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness.Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.Belimumab therapy in systemic lupus erythematosus.Ten developments in the use of biologicals for systemic lupus erythematosus.Aberrant B cell selection and activation in systemic lupus erythematosus.Systemic lupus erythematosus: a therapeutic challenge for the XXI century.Update on B-cell targeted therapies for systemic lupus erythematosus.Emerging biological therapies for systemic lupus erythematosus.Vaccines and biologics.Adverse reactions to biologic agents and their medical management.Update on belimumab for the management of systemic lupus erythematosus.Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies.B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Unintended Immunological Consequences of Biologic Therapy.Acquired Immunity in Chronic Rhinosinusitis.Epigenetic involvement in etiopathogenesis and implications in treatment of systemic lupus erythematous.Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects.[Lupus erythematosus].Systemic lupus erythematosus: immunopathogenesis and novel therapeutic targets.
P2860
Q26827054-6F123CCC-67FF-4648-A854-1970A72D1929Q27007101-94616736-4758-4864-A075-78C6DE9DC00DQ33767123-DCEB715F-A8C2-4356-A4C0-DC59A467255AQ33887820-2E644E45-E12A-4DB0-8386-FBBF9CBDF0D1Q34351248-968BE45A-3475-4ACC-95ED-31825FCA35DFQ34394509-8ACC17DB-102A-4F5C-8E02-21326A4843CCQ35568194-3CAE3295-FD3F-41C0-A5B1-FE20F9086200Q37268312-E66B4D16-317A-4F37-88E7-959697185415Q37616446-A62CAE9A-73CB-431B-B262-A2C1D7B4A824Q37698526-5C65884D-61EA-4528-87C3-BD9B52683FAFQ38095862-227737C6-BC63-4B92-AE70-78C195F95783Q38097328-93C7E328-037B-4122-BB96-9869C89E9672Q38105959-41988F29-B84D-4E0A-9C0E-2EC99E13A574Q38114501-3AC167DE-F5EB-4F67-82C9-56D8D23CABCCQ38191835-2731E0A3-EB10-4657-9292-A1850A96BD79Q38192656-A5F5B9F0-7ADF-4DD2-8EB9-B89F49CFCBACQ38192683-6C990DC4-98DC-4632-93D3-683952968A86Q38213192-339048BD-70A7-46E5-8F99-C8E07BE73887Q38238948-0D2B7FAD-7587-4828-8AFA-2320FB1DBB1AQ38258871-DD9E34F9-DA1B-4572-AFB8-70768AD81357Q38289398-1025EC4F-FF01-40E0-BABC-4C9F318F603EQ38569860-041D29F0-7016-49CA-B3EE-29C4AF101982Q38605480-4B75ED68-373F-40CA-9567-9AEEA4577CB3Q38690844-865A9B14-BC5C-4D07-BC87-F7B9B131CF4FQ38871098-19922C1A-85C2-4CA3-BBB3-088913E6250CQ39379432-71AB1504-08B8-42DB-95E8-3BA470BEC005Q39456337-F19CA5CD-4D23-41EB-A919-C6C55AAC781BQ39816043-BE4E194F-9C66-4F62-AF5A-670AF926BAA7Q41195470-070129AE-03A0-4C88-9B3B-AAE2ED921F6BQ43988095-73E9D8BD-7112-43D8-A9A6-B7BD89D74D47
P2860
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Long-term safety profile of be ...... systemic lupus erythematosus.
@en
Long-term safety profile of be ...... systemic lupus erythematosus.
@nl
type
label
Long-term safety profile of be ...... systemic lupus erythematosus.
@en
Long-term safety profile of be ...... systemic lupus erythematosus.
@nl
prefLabel
Long-term safety profile of be ...... systemic lupus erythematosus.
@en
Long-term safety profile of be ...... systemic lupus erythematosus.
@nl
P2093
P2860
P356
P1476
Long-term safety profile of be ...... systemic lupus erythematosus.
@en
P2093
Cynthia Aranow
Daniel J Wallace
Ellen M Ginzler
Frank R Wellborne
James D McKay
Jeffrey R Lisse
Jerry Klein
Joan T Merrill
John Condemi
LBSL02/99 Study Group
P2860
P304
P356
10.1002/ART.34564
P577
2012-10-01T00:00:00Z